AstraZeneca CEO Pascal Soriot (Getty Images)
September 12, 2020 12:45 PM EDTUpdated September 14, 09:50 AM
R&D
Coronavirus

Six days af­ter a star­tling tri­al halt, As­traZeneca gets a green light to re­sume dos­ing their Ox­ford Covid-19 vac­cine

John Carroll

Editor & Founder

Six days af­ter an abrupt and star­tling halt of their late-stage study of the Ox­ford vac­cine for Covid-19, As­traZeneca is back in busi­ness. And we …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Out­look's shares crash as wet AMD drug flunks Phase 3 test

A service from the Financial Times